Claims for Patent: 5,324,514

Summary for Patent: 5,324,514

Title:	Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
Abstract:	Disclosed are gastric acid-resistant polymer-coated digestive enzymes/ursodeoxycholate compositions, process for their preparations and methods of treating digestive disorders, treating impaired liver function, treating cystic fibrosis, regulating the absorption of dietary cholesterol, and for dissolving gallstones by administering the compositions to a mammal in need of such treatment.
Inventor(s):	Sipos; Tibor (Lebanon, NJ)
Assignee:	Digestive Care Inc. (Lebanon, NJ)
Application Number:	08/104,655
Patent Claims:	1. A digestive enzyme/bile salt composition for the treatment of digestive enzyme/bile salt deficiency of mammals comprising, by weight per weight percentages based on the total weight of the composition: a) from about 71 to about 90.0% of a concentrate of an enzyme selected from the group consisting of pancreatic proteases, lipases, nucleases and amylases; b) from about 0.3 to about 13% of a bile salt in powder form; c) from about 0.8 to about 5% of a buffering agent consisting of anhydrous sodium carbonate, sodium bicarbonate, potassium carbonate or potassium bicarbonate in combination with about 0.8 to about 1.5% tromethamine, diethanolamine or triethanolamine; d) from about 0.9 to about 16% of a disintegrant selected from the group consisting of starch, modified starches, microcrystalline cellulose and propylene glycol alginate; e) from about 0.3 to about 19.0% of an adhesive polymer selected from the group consisting of hydroxypropyl cellulose, polyvinylpyrrolidone, cellulose acetate phthalate, methyl cellulose and propylene glycol alginate; and f) from about 7.0 to about 15% of an non-porous, gastric acid-resistant and pharmaceutically acceptable polymer-coating which contains of from about 0.2 to about 2% talc and which is insoluble in the pH range of from about 1.5 to about 5 but is soluble in the pH range of from about 5.5 to about 9. 2. The composition of claim 1 wherein said digestive enzyme is selected from the group consisting of pancreatin, pancrelipase, trypsin, chymotrypsin, chymotrypsin B, pancreatopeptidase, carboxypeptidase A, carboxypeptidase B, glycerol ester hydrolase, phospholipase A2, sterol ester hydrolase, ribonuclease dioxyribonuclease, .alpha.-amylase, papain, chymopapain, bromelain, picin, .beta.-amylase, cellulase and .beta.-galactosidase. 3. The composition of claim 1 wherein the salt component of said bile acid is selected from the group consisting of sodium, potassium, ammonium, tromethamine, ethanolamine, diethanolamine and triethanolamine. 4. The composition of claim 3 wherein said bile salt is selected from the group consisting of ursodeoxycholate, ethyl ester of ursodeoxycholate, propyl ester of ursodeoxycholate, glycyl ursodeoxycholate, tauroursodeoxycholate, N-methylglycyl ursodeoxycholate and N-methyltaurine ursodeoxycholate. 5. A method for treating digestive enzyme/bile salt deficiency in mammals comprising: orally administering a therapeutically effective amount of the composition of claim 1. 6. The method of claim 5 wherein about 0.5 to 1.5 gms of the composition is administered to a digestive enzyme/bile salt deficient patient with each meal three times a day. 7. The method of claim 6 wherein said composition is administered in an acid soluble capsule containing from about 0.2 to about 0.5 grams of microspheres or microtablets. 8. The method of claim 6 wherein said composition is administered admixed with a liquid or a semi-solid food.

Details for Patent 5,324,514

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Discure Medical, Llc	CHYMODIACTIN	chymopapain	For Injection	018663	November 10, 1982		2012-06-22
Discure Medical, Llc	CHYMODIACTIN	chymopapain	For Injection	018663	August 21, 1984		2012-06-22
Organon Usa Inc., A Subsidiary Of Merck & Co., Inc.	COTAZYM	pancrelipase	Capsule, Delayed Release	020580	December 09, 1996		2012-06-22
Abbvie Inc.	CREON	pancrelipase	Capsule, Delayed Release	020725	April 30, 2009		2012-06-22
Abbvie Inc.	CREON	pancrelipase	Capsule, Delayed Release	020725	June 10, 2011		2012-06-22
Abbvie Inc.	CREON	pancrelipase	Capsule, Delayed Release	020725	March 14, 2013		2012-06-22

International Patent Family for US Patent 5,324,514

Country	Patent Number	Estimated Expiration
Australia	4133193
Australia	666015
Canada	2096002
European Patent Office	0576938
United States of America	5260074
United States of America	5460812